Cargando…
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials
Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson’s disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep,...
Autores principales: | Goldman, Jennifer G., Forsberg, Leah K., Boeve, Bradley F., Armstrong, Melissa J., Irwin, David J., Ferman, Tanis J., Galasko, Doug, Galvin, James E., Kaufer, Daniel, Leverenz, James, Lippa, Carol F., Marder, Karen, Abler, Victor, Biglan, Kevin, Irizarry, Michael, Keller, Bill, Munsie, Leanne, Nakagawa, Masaki, Taylor, Angela, Graham, Todd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597002/ https://www.ncbi.nlm.nih.gov/pubmed/33121510 http://dx.doi.org/10.1186/s13195-020-00703-5 |
Ejemplares similares
-
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting
por: Goldman, Jennifer G., et al.
Publicado: (2021) -
Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel
por: Sabbagh, Marwan N., et al.
Publicado: (2023) -
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
por: McKeith, Ian G., et al.
Publicado: (2020) -
Arguing against the proposed definition changes of PD
por: Boeve, Bradley F., et al.
Publicado: (2016) -
Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial
por: Biglan, Kevin, et al.
Publicado: (2021)